Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRASS2: Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for High Risk RetroPeritoneal Sarcoma
NCT04031677Phase 3Recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jan 2021
- Primary completion
- Apr 2027
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 15
01
Overview
Phase 3, randomised, open-label trial of pegylated liposomal doxorubicin, ifosfamide and dacarbazine in retroperitoneal sarcoma (RPS), Liposarcoma and leiomyosarcoma (LMS) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Disease free survival at 7 years. Started Jan 2021; status: recruiting.
02
Drugs
pegylated liposomal doxorubicinifosfamidedacarbazine
03
Conditions
retroperitoneal sarcoma (RPS)Liposarcomaleiomyosarcoma (LMS)
Beyond the preview
Go deeper on NCT04031677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04031677.